Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andro Targeted By FDA In Coordination With Capitol Hill Action

This article was originally published in The Tan Sheet

Executive Summary

FDA is aiming to remove androstenedione supplements from the market by classifying the substance as a new dietary ingredient that has not been the subject of a safety notification to the agency, as required by the Dietary Supplement Health & Education Act

Related Content

MLB Controversy Spotlights Line Between Steroids, Supplements
FDA Enforcement Of NDI Filings Lacks Consistency, Industry Reps Say
Carb-Blocking Supplement Marketers Served With FDA Warning Letters
DSHEA Strategy: “Signal Detection” Is First Defense To Detect Adverse Events
FDA New Dietary Ingredient Meeting To Focus On Submission Shortfalls
75-Day Dietary Ingredient Notification Process Needs Revision – McGuffin
FDA Miscasts “Dietary Substance” In Statements On DSHEA – Petition
Steroid Bill Clears House Judiciary Committee; Senate Floor Next?
Consumer Reports Article Highlights “Dangerous” Supplements
DHEA Controlled Substance Status Sought By Sweeney Under Andro Bill





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts